Wells Fargo’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.8M | Buy |
79,871
+2,455
| +3% | +$455K | ﹤0.01% | 1786 |
|
|
2025
Q4 | $15.4M | Sell |
77,416
-2,551
| -3% | -$463K | ﹤0.01% | 1696 |
|
|
2025
Q3 | $12.5M | Buy |
79,967
+1,126
| +1% | +$179K | ﹤0.01% | 1811 |
|
|
2025
Q2 | $12M | Sell |
78,841
-389,193
| -83% | -$51.9M | ﹤0.01% | 1769 |
|
|
2025
Q1 | $70.4M | Sell |
468,034
-15,480
| -3% | -$2.6M | 0.02% | 667 |
|
|
2024
Q4 | $89.3M | Sell |
483,514
-68,283
| -12% | -$13.2M | 0.02% | 572 |
|
|
2024
Q3 | $109M | Sell |
551,797
-9,325
| -2% | -$1.94M | 0.02% | 512 |
|
|
2024
Q2 | $116M | Sell |
561,122
-8,293
| -1% | -$1.88M | 0.03% | 463 |
|
|
2024
Q1 | $154M | Buy |
569,415
+23,890
| +4% | +$5.71M | 0.04% | 363 |
|
|
2023
Q4 | $129M | Sell |
545,525
-27,223
| -5% | -$5.35M | 0.03% | 384 |
|
|
2023
Q3 | $112M | Buy |
572,748
+28,413
| +5% | +$5.83M | 0.03% | 397 |
|
|
2023
Q2 | $114M | Buy |
544,335
+33,721
| +7% | +$6.71M | 0.03% | 402 |
|
|
2023
Q1 | $103M | Buy |
510,614
+43,065
| +9% | +$9.76M | 0.03% | 419 |
|
|
2022
Q4 | $102M | Sell |
467,549
-17,165
| -4% | -$3.75M | 0.03% | 424 |
|
|
2022
Q3 | $95.4M | Buy |
484,714
+20,835
| +4% | +$4.5M | 0.03% | 411 |
|
|
2022
Q2 | $99.3M | Sell |
463,879
-24,465
| -5% | -$5.98M | 0.03% | 418 |
|
|
2022
Q1 | $139M | Buy |
488,344
+144,662
| +42% | +$44.6M | 0.04% | 391 |
|
|
2021
Q4 | $129M | Buy |
343,682
+33,138
| +11% | +$12.9M | 0.03% | 395 |
|
|
2021
Q3 | $128M | Sell |
310,544
-13,792
| -4% | -$5.73M | 0.03% | 550 |
|
|
2021
Q2 | $120M | Sell |
324,336
-70,764
| -18% | -$23.6M | 0.03% | 581 |
|
|
2021
Q1 | $115M | Sell |
395,100
-126,475
| -24% | -$35.2M | 0.03% | 599 |
|
|
2020
Q4 | $130M | Sell |
521,575
-492,006
| -49% | -$117M | 0.03% | 519 |
|
|
2020
Q3 | $230M | Sell |
1,013,581
-184,329
| -15% | -$38.3M | 0.06% | 295 |
|
|
2020
Q2 | $209M | Buy |
1,197,910
+62,244
| +5% | +$9.93M | 0.06% | 298 |
|
|
2020
Q1 | $143M | Sell |
1,135,666
-78,776
| -6% | -$11.8M | 0.05% | 353 |
|
|
2019
Q4 | $186M | Sell |
1,214,442
-24,111
| -2% | -$3.34M | 0.05% | 372 |
|
|
2019
Q3 | $164M | Buy |
1,238,553
+203,025
| +20% | +$27.2M | 0.05% | 393 |
|
|
2019
Q2 | $147M | Sell |
1,035,528
-10,359
| -1% | -$1.41M | 0.04% | 429 |
|
|
2019
Q1 | $152M | Sell |
1,045,887
-426,992
| -29% | -$56.1M | 0.05% | 412 |
|
|
2018
Q4 | $167M | Buy |
1,472,879
+78,815
| +6% | +$9.87M | 0.06% | 335 |
|
|
2018
Q3 | $188M | Buy |
1,394,064
+77,429
| +6% | +$9.56M | 0.05% | 365 |
|
|
2018
Q2 | $148M | Buy |
1,316,635
+67,439
| +5% | +$7.29M | 0.04% | 432 |
|
|
2018
Q1 | $133M | Buy |
1,249,196
+1,010,618
| +424% | +$109M | 0.04% | 461 |
|
|
2017
Q4 | $26.1M | Buy |
238,578
+152,689
| +178% | +$16.6M | 0.01% | 1294 |
|
|
2017
Q3 | $9.28M | Buy |
85,889
+4,807
| +6% | +$494K | ﹤0.01% | 2029 |
|
|
2017
Q2 | $8.2M | Buy |
81,082
+32,299
| +66% | +$2.97M | ﹤0.01% | 2070 |
|
|
2017
Q1 | $4.39M | Sell |
48,783
-18,773
| -28% | -$1.59M | ﹤0.01% | 2532 |
|
|
2016
Q4 | $5.15M | Buy |
67,556
+7,020
| +12% | +$533K | ﹤0.01% | 2381 |
|
|
2016
Q3 | $5.04M | Sell |
60,536
-4,028
| -6% | -$338K | ﹤0.01% | 2271 |
|
|
2016
Q2 | $5.32M | Sell |
64,564
-25,623
| -28% | -$2.11M | ﹤0.01% | 2266 |
|
|
2016
Q1 | $6.85M | Buy |
90,187
+29,757
| +49% | +$2.2M | ﹤0.01% | 2069 |
|
|
2015
Q4 | $4.86M | Sell |
60,430
-210,159
| -78% | -$15.2M | ﹤0.01% | 2348 |
|
|
2015
Q3 | $17.2M | Sell |
270,589
-2,668
| -1% | -$192K | 0.01% | 1396 |
|
|
2015
Q2 | $19.2M | Sell |
273,257
-20,345
| -7% | -$1.51M | 0.01% | 1399 |
|
|
2015
Q1 | $23.3M | Sell |
293,602
-189,122
| -39% | -$14M | 0.01% | 1225 |
|
|
2014
Q4 | $30.7M | Sell |
482,724
-21,097
| -4% | -$1.32M | 0.01% | 1030 |
|
|
2014
Q3 | $30.1M | Sell |
503,821
-143,848
| -22% | -$8.23M | 0.01% | 1012 |
|
|
2014
Q2 | $34.7M | Sell |
647,669
-39,897
| -6% | -$2.19M | 0.01% | 958 |
|
|
2014
Q1 | $41.5M | Sell |
687,566
-122,430
| -15% | -$7.14M | 0.02% | 850 |
|
|
2013
Q4 | $43M | Buy |
809,996
+107,918
| +15% | +$5.42M | 0.02% | 826 |
|
|
2013
Q3 | $32.5M | Buy |
702,078
+91,726
| +15% | +$4.21M | 0.02% | 906 |
|
|
2013
Q2 | $25M | Buy |
+610,352
| New | +$26.2M | 0.01% | 993 |
|
Other funds holding CRL
VCM
VPM
Wells Fargo's CRL Position: Q1 2026 in Review
Wells Fargo increased its Charles River Laboratories (CRL) stake by 3.2% in Q1 2026, buying an estimated $455K and bringing the position to 79,871 shares worth $13.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1786.
Wells Fargo first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. The position peaked at $230M in Q3 2020. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Wells Fargo held 79,871 shares of Charles River Laboratories worth $13.8M as of Q1 2026.
- Wells Fargo bought 2,455 Charles River Laboratories shares in Q1 2026, an estimated $455K.
- Charles River Laboratories made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #1786 holding.
- Wells Fargo first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
- Wells Fargo's Charles River Laboratories position peaked at $230M in Q3 2020.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.